Drug interactions
Liposomal doxorubicin + Ponatinib
Severity: Moderate
Liposomal doxorubicin and Ponatinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ponatinib inhibits P-glycoprotein and may raise doxorubicin exposure, which could increase toxicity. Both drugs also carry cardiotoxicity and myelosuppression risks that may add together.
What this interaction means in plain words
Liposomal doxorubicin and Ponatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Liposomal doxorubicin belongs to Oncology; Ponatinib belongs to Oncology.
Why it happens
Ponatinib inhibits P-gp efflux, potentially reducing doxorubicin elimination, with additive cardiac and marrow toxicity.
What to do
Monitor blood counts and cardiac function (LVEF, blood pressure, heart failure symptoms). Reduce doses if toxicity emerges.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Liposomal doxorubicin and Ponatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Other interactions of Ponatinib
Frequently asked questions
Can I take Liposomal doxorubicin with Ponatinib?
MediHelp rates the interaction as moderate. Liposomal doxorubicin and Ponatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ponatinib inhibits P-glycoprotein and may raise doxorubicin exposure, which could increase toxicity. Both drugs also carry cardiotoxicity and myelosuppression risks that may add together.
How serious is the interaction between Liposomal doxorubicin and Ponatinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and cardiac function (LVEF, blood pressure, heart failure symptoms). Reduce doses if toxicity emerges.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
